Based on this finding, the FDA has approved pembrolizumab plus trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced or metastatic HER2- and PD-L1-positive (CPS≥1) gastric/GEJ adenocarcinoma. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.